MAM-treated mice showed decreased numbers of GABA interneurons and PPI deficits rescued by a 6 week EE application and local DG infusion of the GABAAR agonist muscimol. A, Representative GAD67-EGFP and PV staining in the DG. Scale bar, 200 μm. B, C, The numbers of (B) GAD67-EGFP+ cells (F(1,14) = 14.90636, p = 0.00173 for MAM vs saline, n = 8 for each group) and (C) PV+ cells (F(1,14) = 7.85009, p = 0.01413 for MAM vs saline, n = 8 for each group) in the DG were decreased by MAM treatment. D, There were no changes in the numbers of PV+ cells in non-neurogenic regions (CA1, CA2, and CA3) (F(1,14) = 2.7165, p = 0.12157 for MAM vs saline, n = 8 samples for each group). E, The groups of mice were bilaterally implanted with cannulae into DG at PW8.5 and locally infused with muscimol at PW10 (left). As shown, PPI deficits were observed in the MAM group at PW10 (2-way ANOVA with group treatment and prepulse intensity: F(9,44) = 0.885, p = 0.546; 1-way ANOVA with PP3: F(1,10) = 6.80619, p = 0.03119; PP6: F(1,10) = 17.16855, p = 0.00324; PP12: F(1,10) = 49.75486, p = 0.000113 for saline plus saline vehicle group vs MAM plus saline vehicle group) and these deficits were further rescued by a local DG muscimol infusion of 10 ng/per hemisphere (PP3: F(1,10) = 5.36461, p = 0.04921; PP6: F(1,10) = 6.0888, p = 0.03886; PP12: F(1,10) = 14.19858, p = 0.00548 for MAM plus saline vehicle group vs MAM plus 10 ng/per hemisphere muscimol group), but not by a local DG muscimol infusion of 100 ng/per hemisphere (PP3: F(1,10) = 1.77437, p = 0.21954; PP6: F(1,10) = 0.16899, p = 0.6918; PP12: F(1,10) = 0.00142, p = 0.97089 for MAM plus saline vehicle group vs MAM plus 100 ng/per hemisphere muscimol group, n = 6 mice for each group). F, Representative images for bilaterally local injection of FITC (left, 50 ng/per hemisphere; right, 500 ng/per hemisphere) into DG to visualize the spread of muscimol. Scale bar, 200 μm. *p < 0.05; **p < 0.01.